Prazopress ER Tablet 2.5mg10 tablets
Prazopress-ER 2.5 tablet: Light violet, round-shaped tablet; each extended release tablet contains Prazosin Hydrochloride BP
equivalent to Prazosin 2.5mg.
Prazopress-ER 5 tablet: Light green, round-shaped tablet; each extended release tablet contains Prazosin Hydrochloride BP
equivalent to Prazosin 5mg.
Prazosin extended release tablet is indicated in the treatment of mild to moderate essential hypertension. It is employed in a
general treatment program in association with a thiazide diuretic and/or other antihypertensive agents as needed for proper
Dosage & administration
Dosage should be individualized depending on patient tolerance and response. Therapy for hypertension must be initiated with
Prazosin extended release 2.5mg once daily. Prazosin extended release 5mg is not for initial dosing. Dosage may be increased
slowly, in general over a 7 to 14 day period, depending on the response to each dose level. Doses above 20mg once daily have not
Maintenance dose: dosage may be increased as clinically indicated to 20mg given in once-daily doses. Hypertensive patients
controlled on Prazosin tablets alone or in combination with other antihypertensive medications may be switched to Prazosin
extended release tablets at the equivalent or nearest higher total daily dose, e.g. Prazosin tablets 4 mg daily equivalent to
Prazosin extended release tablets 5 mg once daily. Blood pressure measurements should be taken at the end of the dosing interval
to assure adequate blood pressure control is maintained throughout the 24 hour period. Further titration may be necessary in some
Contraindications, warnings etc.
Contraindication: Prazosin extended release tablet is contraindicated in patients with a known sensitivity to quinazolines.
Warnings: Prazosin may cause syncope and/or excessive hypotension with sudden loss of consciousness. In most cases, this is
believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by
about of severe tachycardia with heart rates of 120-160 beats per minute. To decrease the likelihood of syncope or excessive
hypotension, treatment should always be initiated with Prazosin extended release 2.5 mg tablet. The 5 mg tablet is not indicated
as initial therapy. Patients should be made aware of the possibility of occurrence of symptoms associated with lowering of blood
pressure e.g. orthostatic symptoms, especially at the initiation of therapy and to avoid driving or hazardous tasks for 24 hours
after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. Dizziness,
lightheadedness or fainting may occur, especially when rising from a supine or sitting position. If such an event occurs, patients
should be advised to lie down. Getting up slowly and going from a supine to a sitting position before standing up may help reduce
the problem. As with most other antihypertensive agents, while taking Prazosin extended release tablet patients should be careful
of their alcohol intake, use extra care during exercise or hot weather, and avoid standing for long periods, all of which can
contribute to the occurrence of orthostatic symptoms. If dizziness, lightheadedness, or palpitations are bothersome they should be
reported to the physician.
In patients with congestive cardiac failure: Prazosin is not recommended in the treatment of congestive cardiac failure due to
mechanical obstruction such as aortic valve stenosis, mitral valve stenosis, pulmonary embolism and restrictive pericardial
disease. Adequate data are not yet available to establish efficacy in patients with heart failure due to recent myocardial
Drug Interactions: Prazosin has been administered without any adverse drug interaction in clinical experience to date with the
following: Digitalis and digoxin, insulin, chlorpropamide, phenformin, tolazamide and tolbutamide, chlordiazepoxide, diazepam and
Phenobarbital, allopurinol, colchicine and probenecid, procainamide, propranolol and quinidine, propoxyphene, aspirin,
indomethacin and phenylbutazone. Interaction studies have not been performed with Prazosin extended release tablet. Addition of a
diuretic or other antihypertensive agent to Prazosin extended release tablet has been shown to cause an additive hypotensive
effect. An exaggerated hypotensive response has also been observed.
Use in Pregnancy and Lactation: Although no teratogenic effects were seen in animal testing, there are no adequate and well
controlled studies which establish the safety of Prazosin extended release tablet in pregnant women. Prazosin extended release
tablet should be used during pregnancy only if in the opinion of the physician the potential benefit outweighs potential risk to
mother and child. Prazosin has been shown to be excreted in small amounts in human milk. Caution should be exercised when Prazosin
extended release tablet is administered to nursing mothers.
Adverse Reactions: Four hundred and eighty one (481) hypertensive patients from placebo controlled multiple-dose trials treated
with Prazosin extended release tablets were included in the evaluation of adverse effects. Adverse reactions requiring
discontinuation of therapy occurred in 2.9% of patients. In controlled clinical trials in 689 patients, the most serious adverse
reaction was syncope which occurred in one patient (0.1%) on the fourth day of dosing with Prazosin extended release tablet. The
most common adverse effects reported with Prazosin extended release tablet were headache, dizziness, fatigue, edema and
Overdose: Accidental ingestion of at least 50 mg of prazosin in a 2-year old child resulted in profound drowsiness and depressed
reflexes. No decrease in blood pressure was noted. Recovery was uneventful. Should over-dosage lead to hypotension, support of the
cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by
keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If
necessary, vasopressors including angiotensin should then be used. Renal function should be monitored and supported as needed.
Laboratory data indicate Prazosin is not dialysable because it is protein bound.
Store in a cool and dry place, protected from light.
Prazopress-ER 2.5 tablet: Carton contains 20 tablets in alu-alu blister.
Prazopress-ER 5 tablet: Carton contains 20 tablets in alu-alu blister.